EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets

Moses Ocan iD, Winnie Nambatya, Caroline Otike, Loyce Nakalembe, Sam Nsobya

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0295198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Moses Ocan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology & Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Malaria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EDCTP2.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malaria remains one of the leading causes of morbidity, and mortality in Uganda. A large proportion of malaria symptomatic patients seek healthcare in private sector. However, availability and affordability are major barriers to access to effective treatment. The private sector copayment mechanism in Uganda aims to increase availability and affordability of antimalarial agents. Our study assessed availability, price, and market share of quality assured artemisinin-based combination therapies (QAACTs) in private drug outlets in selected districts during the implementation of copayment mechanism.

Methods

This was a cross-sectional survey of anti-malarial agents in private drug outlets in in selected moderate-to-high (Tororo, and Apac districts) and low (Kabale and Mbarara districts) malaria transmission settings. Following the World Health Organization/Health Action International (WHO/HAI) criteria, an audit of the antimalarial agents was done using a checklist to determine availability, price, and market share of QAACTs. Data were entered in Epi-data and analyzed in STATA ver 14.0 at 95% confidence level.

Results

A total of twenty-eight (28) private drug outlets (pharmacies and drug shops) were included in the survey. One in seven (20/144: 95%CI: 9.1, 20.6) of the antimalarial agents in private drug outlets were quality assured artemisinin-based combination therapies (QAACT). Artemether-lumefantrine (AL), 8.9% (11/124) and Artesunate-Amodiaquine (AQ), 7.3% (9/124) were the only QAACTs present in the drug outlets at the time of the survey. The majority, 86.1%% (124/144) of antimalarial agents present in stock in the drug outlets were artemisinin based. The most common, 38.9% (56/144) ACT in the drug outlets was Dihydroartemisinin-Piperaquine (DHP). Most, 69.4% (100/144) of the antimalarial agents were in high malaria transmission settings. The cost of ACT antimalarial agents is high in the country, USD 1.4 (Artemether-Lumefantrine, AL), USD 2.4 (Dihydroartemisinin-Piperaquine, DP), the first line and second-line agents respectively for treatment of uncomplicated malaria in Uganda. There was a statistically significant difference between the dispensing price of ‘Green leaf’ ACTs (QAACT) and the recommended price ( p< 0.001). Predictors of availability of QAACT in private drug outlets include pharmacy drug outlet (aPR:0.4; 95%CI: 0.2, 0.9) and dispensing price more than 3000UGX (USD 0.83) (aPR: 0.4, 95%CI: 0.1, 0.51).

Conclusion

Quality assured artemisinin-based combination therapies (QAACTs) are not common in private drug outlets in selected districts in Uganda. All the drug outlets had at least one ACT antimalarial agent present on the day of the survey. The dispensing price of QAACTs was significantly higher than the recommended markup price. There is need for awareness creation, surveillance, and monitoring of the implementation of Copayment mechanism in the country.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsArtemisininsMalariaHumansUgandaCross-Sectional StudiesArtemether, Lumefantrine Drug CombinationArtemether

Substanzen

artenimolAntimalarialsArtemether, Lumefantrine Drug CombinationArtemetherArtemisininsartemisinin

Autor:innen und Institutionen

  • Department of Pharmacology & Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Department of Clinical Pharmacy, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Data Department, Joint Clinical Research Centre, Lubowa, Kampala, Uganda.
  • Department of Pharmacology, Soroti University, Soroti, Uganda.
  • Department of Pathology, College of Health Sciences, Makerere University, Kampala, Uganda.

ORCID-Profile: Moses Ocan

Förderung

  • EDCTP2

Zitieren

APA

Ocan, M., Nambatya, W., Otike, C., Nakalembe, L., & Nsobya, S. (2024). Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets. PLOS ONE. https://doi.org/10.1371/journal.pone.0295198

Vancouver

Ocan M, Nambatya W, Otike C, Nakalembe L, Nsobya S. Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets. PLOS ONE. 2024. doi:10.1371/journal.pone.0295198

BibTeX
@article{Ocan2024,
  author = {Ocan, Moses and Nambatya, Winnie and Otike, Caroline and Nakalembe, Loyce and Nsobya, Sam},
  title = {Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0295198}
}
Kostenlos starten →